{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T22:47:47Z","timestamp":1777848467339,"version":"3.51.4"},"reference-count":58,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1416_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Chemoradiotherapy (CRT) alone shows limited efficacy in improving outcomes for metastatic colorectal cancer (mCRC) patients. This study aimed to comprehensively evaluate the survival benefits of combining CRT with immunotherapy (CRT\u00a0+\u00a0IMT) in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1416_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the SEER database were extracted for mCRC patients diagnosed between 2010\u20132015 and 2018\u20132020. Survival outcomes were assessed using Kaplan\u2013Meier analysis, log-rank test, Cox regression, and propensity score matching (PSM) to minimize baseline differences between treatment groups, and multivariable Cox models were constructed based on variables selected by LASSO regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1416_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,451 patients were identified, with 1,888 receiving CRT alone and 563 CRT\u00a0+\u00a0IMT. After 1:2 PSM, 1,594 remained. Kaplan\u2013Meier curves showed CRT\u00a0+\u00a0IMT significantly improved overall survival (OS, p&lt;0.0001) and cancer-specific survival (CSS, p&lt;0.0001). Multivariable Cox confirmed CRT\u00a0+\u00a0IMT as an independent predictor (OS HR=0.54, 95\u202f% CI: 0.44\u20130.65; CSS HR=0.54, 95\u202f% CI: 0.44\u20130.66). Favorable factors included distal colon\/rectal tumors, surgery, and combined therapy, while older age (&gt;60), advanced stage, N2, and metastasis predicted worse survival. The subgroup analyses revealed a more pronounced benefit in specific cohorts, and significant interactions were observed for factors such as histologic grade and nodal\u00a0stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1416_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of CRT and immunotherapy confers a significant survival advantage over CRT alone in patients with mCRC, supporting its potential role in optimized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1416","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:34:41Z","timestamp":1777498481000},"source":"Crossref","is-referenced-by-count":0,"title":["Survival benefits of immunotherapy combined with chemoradiotherapy in metastatic colorectal cancer: an analysis based on data from the SEER database"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9802-6692","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy , Jingjiang People\u2019s Hospital Affiliated to Yangzhou University , Jingjiang , Jiangsu , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4708-8802","authenticated-orcid":false,"given":"Weijuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy , Jingjiang People\u2019s Hospital Affiliated to Yangzhou University , Jingjiang , Jiangsu , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026042921165970084_j_med-2026-1416_ref_001","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Wagle, NS, Cercek, A, Smith, RA, Jemal, A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023;73:233\u201354. https:\/\/doi.org\/10.3322\/caac.21772.","DOI":"10.3322\/caac.21772"},{"key":"2026042921165970084_j_med-2026-1416_ref_002","doi-asserted-by":"crossref","unstructured":"Kanth, P, Inadomi, JM. Screening and prevention of colorectal cancer. BMJ 2021;374.","DOI":"10.1136\/bmj.n1855"},{"key":"2026042921165970084_j_med-2026-1416_ref_003","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Miller, KD, Fedewa, SA, Ahnen, DJ, Meester, RG, Barzi, A, et al.. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017;67:177\u201393. https:\/\/doi.org\/10.3322\/caac.21395.","DOI":"10.3322\/caac.21395"},{"key":"2026042921165970084_j_med-2026-1416_ref_004","doi-asserted-by":"crossref","unstructured":"Dekker, E, Tanis, PJ, Vleugels, JL, Kasi, PM, Wallace, MB. Colorectal cancer. Lancet (London, England) 2019;394:1467\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(19)32319-0.","DOI":"10.1016\/S0140-6736(19)32319-0"},{"key":"2026042921165970084_j_med-2026-1416_ref_005","doi-asserted-by":"crossref","unstructured":"Biller, LH, Schrag, D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 2021;325:669\u201385. https:\/\/doi.org\/10.1001\/jama.2021.0106.","DOI":"10.1001\/jama.2021.0106"},{"key":"2026042921165970084_j_med-2026-1416_ref_006","doi-asserted-by":"crossref","unstructured":"Underwood, PW, Ruff, SM, Pawlik, TM. Update on targeted therapy and immunotherapy for metastatic colorectal cancer. Cells 2024;13:245. https:\/\/doi.org\/10.3390\/cells13030245.","DOI":"10.3390\/cells13030245"},{"key":"2026042921165970084_j_med-2026-1416_ref_007","doi-asserted-by":"crossref","unstructured":"Rumpold, H, Nieders\u00fc\u00df-Beke, D, Heiler, C, Falch, D, Wundsam, HV, Metz-Gercek, S, et al.. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer 2020;20:1\u20139.","DOI":"10.1186\/s12885-020-07656-w"},{"key":"2026042921165970084_j_med-2026-1416_ref_008","doi-asserted-by":"crossref","unstructured":"Stebbing, J, Wasan, HS. Decoding metastatic colorectal cancer to improve clinical decision making. Alexandria, VA: American Society of Clinical Oncology; 2019:1847\u201350 pp.","DOI":"10.1200\/JCO.19.01185"},{"key":"2026042921165970084_j_med-2026-1416_ref_009","doi-asserted-by":"crossref","unstructured":"Benson, AB, Venook, AP, Adam, M, Chang, G, Chen, Y-J, Ciombor, KK, et al.. Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J\u00a0Natl Compr Cancer Netw 2024;22. https:\/\/doi.org\/10.6004\/jnccn.2024.0029.","DOI":"10.6004\/jnccn.2024.0029"},{"key":"2026042921165970084_j_med-2026-1416_ref_010","doi-asserted-by":"crossref","unstructured":"Chau, I, Cunningham, D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009;100:1704\u201319. https:\/\/doi.org\/10.1038\/sj.bjc.6605061.","DOI":"10.1038\/sj.bjc.6605061"},{"key":"2026042921165970084_j_med-2026-1416_ref_011","doi-asserted-by":"crossref","unstructured":"Le, DT, Durham, JN, Smith, KN, Wang, H, Bartlett, BR, Aulakh, LK, et al.. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","DOI":"10.1126\/science.aan6733"},{"key":"2026042921165970084_j_med-2026-1416_ref_012","doi-asserted-by":"crossref","unstructured":"Overman, MJ, McDermott, R, Leach, JL, Lonardi, S, Lenz, H-J, Morse, MA, et al.. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182\u201391. https:\/\/doi.org\/10.1016\/s1470-2045(17)30422-9.","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"2026042921165970084_j_med-2026-1416_ref_013","doi-asserted-by":"crossref","unstructured":"Sun, H, Shi, K, Qi, K, Kong, H, He, Q, Zhou, M. Pseudostellaria heterophylla extract polysaccharide H-1-2 suppresses pancreatic cancer by inhibiting hypoxia-induced AG2. Mol Ther Oncolytics 2020;17:61\u20139. https:\/\/doi.org\/10.1016\/j.omto.2020.03.007.","DOI":"10.1016\/j.omto.2020.03.007"},{"key":"2026042921165970084_j_med-2026-1416_ref_014","doi-asserted-by":"crossref","unstructured":"Le, DT, Kim, TW, Van Cutsem, E, Geva, R, J\u00e4ger, D, Hara, H, et al.. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164. J\u00a0Clin Oncol 2020;38:11\u20139. https:\/\/doi.org\/10.1200\/jco.19.02107.","DOI":"10.1200\/JCO.19.02107"},{"key":"2026042921165970084_j_med-2026-1416_ref_015","doi-asserted-by":"crossref","unstructured":"Arrichiello, G, Poliero, L, Borrelli, C, Paragliola, F, Nacca, V, Napolitano, S, et al.. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? Cancer Treat Res Commun 2021;28:100442. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100442.","DOI":"10.1016\/j.ctarc.2021.100442"},{"key":"2026042921165970084_j_med-2026-1416_ref_016","doi-asserted-by":"crossref","unstructured":"Leowattana, W, Leowattana, P, Leowattana, T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol 2023;29:1569\u201388. https:\/\/doi.org\/10.3748\/wjg.v29.i10.1569.","DOI":"10.3748\/wjg.v29.i10.1569"},{"key":"2026042921165970084_j_med-2026-1416_ref_017","doi-asserted-by":"crossref","unstructured":"Watkinson, R, Tam, J, Vaysburd, M, James, L. Simultaneous neutralization and innate immune detection of a replicating virus by TRIM21. J\u00a0Virol 2013;87:7309\u201313. https:\/\/doi.org\/10.1128\/jvi.00647-13.","DOI":"10.1128\/JVI.00647-13"},{"key":"2026042921165970084_j_med-2026-1416_ref_018","doi-asserted-by":"crossref","unstructured":"Wang, W, Wu, L, Zhang, J, Wu, H, Han, E, Guo, Q. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Biochem Biophys Res Commun 2017;487:1\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.180.","DOI":"10.1016\/j.bbrc.2016.12.180"},{"key":"2026042921165970084_j_med-2026-1416_ref_019","doi-asserted-by":"crossref","unstructured":"Kanterman, J, Sade-Feldman, M, Biton, M, Ish-Shalom, E, Lasry, A, Goldshtein, A, et al.. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res 2014;74:6022\u201335. https:\/\/doi.org\/10.1158\/0008-5472.can-14-0657.","DOI":"10.1158\/0008-5472.CAN-14-0657"},{"key":"2026042921165970084_j_med-2026-1416_ref_020","doi-asserted-by":"crossref","unstructured":"Lote, H, Starling, N, Pihlak, R, Gerlinger, M. Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treat Rev 2022;111:102480. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102480.","DOI":"10.1016\/j.ctrv.2022.102480"},{"key":"2026042921165970084_j_med-2026-1416_ref_021","doi-asserted-by":"crossref","unstructured":"Pfirschke, C, Engblom, C, Rickelt, S, Cortez-Retamozo, V, Garris, C, Pucci, F, et al.. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016;44:343\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2015.11.024.","DOI":"10.1016\/j.immuni.2015.11.024"},{"key":"2026042921165970084_j_med-2026-1416_ref_022","doi-asserted-by":"crossref","unstructured":"Herting, CJ, Farren, MR, Tong, Y, Liu, Z, O\u2019Neil, B, Bekaii-Saab, T, et al.. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother 2021;70:3337\u201348. https:\/\/doi.org\/10.1007\/s00262-021-02986-5.","DOI":"10.1007\/s00262-021-02986-5"},{"key":"2026042921165970084_j_med-2026-1416_ref_023","doi-asserted-by":"crossref","unstructured":"Antoniotti, C, Rossini, D, Pietrantonio, F, Catteau, A, Salvatore, L, Lonardi, S, et al.. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2022;23:876\u201387. https:\/\/doi.org\/10.1016\/s1470-2045(22)00274-1.","DOI":"10.1016\/S1470-2045(22)00274-1"},{"key":"2026042921165970084_j_med-2026-1416_ref_024","doi-asserted-by":"crossref","unstructured":"Parikh, AR, Szabolcs, A, Allen, JN, Clark, JW, Wo, JY, Raabe, M, et al.. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer 2021;2:1124\u201335. https:\/\/doi.org\/10.1038\/s43018-021-00269-7.","DOI":"10.1038\/s43018-021-00269-7"},{"key":"2026042921165970084_j_med-2026-1416_ref_025","doi-asserted-by":"crossref","unstructured":"Segal, NH, Kemeny, NE, Cercek, A, Reidy, DL, Raasch, PJ, Warren, P, et al.. Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. Alexandria, VA: American Society of Clinical Oncology; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.3539"},{"key":"2026042921165970084_j_med-2026-1416_ref_026","doi-asserted-by":"crossref","unstructured":"Ganesh, K, Stadler, ZK, Cercek, A, Mendelsohn, RB, Shia, J, Segal, NH, et al.. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 2019;16:361\u201375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x.","DOI":"10.1038\/s41575-019-0126-x"},{"key":"2026042921165970084_j_med-2026-1416_ref_027","doi-asserted-by":"crossref","unstructured":"Borelli, B, Antoniotti, C, Carullo, M, Germani, MM, Conca, V, Masi, G. Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability. Cancers 2022;14:4974. https:\/\/doi.org\/10.3390\/cancers14204974.","DOI":"10.3390\/cancers14204974"},{"key":"2026042921165970084_j_med-2026-1416_ref_028","doi-asserted-by":"crossref","unstructured":"Moretto, R, Elliott, A, Zhang, J, Arai, H, Germani, MM, Conca, V, et al.. Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications. JNCI (J Natl Cancer Inst) 2022;114:271\u20139. https:\/\/doi.org\/10.1093\/jnci\/djab169.","DOI":"10.1093\/jnci\/djab169"},{"key":"2026042921165970084_j_med-2026-1416_ref_029","doi-asserted-by":"crossref","unstructured":"Ree, AH, Hamre, H, Kersten, C, Hofsli, E, Guren, MG, Sorbye, H, et al.. Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): initial results from the randomized METIMMOX study. Philadelphia, PA: Wolters Kluwer Health; 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.3556"},{"key":"2026042921165970084_j_med-2026-1416_ref_030","doi-asserted-by":"crossref","unstructured":"Xue, M, Tian, Y, Sui, Y, Zhao, H, Gao, H, Liang, H, et al.. Protective effect of fucoidan against iron overload and ferroptosis-induced liver injury in rats exposed to alcohol. Biomed Pharmacother 2022;153:113402. https:\/\/doi.org\/10.1016\/j.biopha.2022.113402.","DOI":"10.1016\/j.biopha.2022.113402"},{"key":"2026042921165970084_j_med-2026-1416_ref_031","doi-asserted-by":"crossref","unstructured":"Voronova, V, Vislobokova, A, Mutig, K, Samsonov, M, Peskov, K, Sekacheva, M, et al.. Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance. Front Oncol 2022;12:1035884. https:\/\/doi.org\/10.3389\/fonc.2022.1035884.","DOI":"10.3389\/fonc.2022.1035884"},{"key":"2026042921165970084_j_med-2026-1416_ref_032","doi-asserted-by":"crossref","unstructured":"Yuki, S, Bando, H, Tsukada, Y, Inamori, K, Komatsu, Y, Homma, S, et al.. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Alexandria, VA: American Society of Clinical Oncology; 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.4100"},{"key":"2026042921165970084_j_med-2026-1416_ref_033","doi-asserted-by":"crossref","unstructured":"Salvatore, L, Bensi, M, Corallo, S, Bergamo, F, Pellegrini, I, Rasola, C, et al.. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA study. Philadelphia, PA: Wolters Kluwer Health; 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.3511"},{"key":"2026042921165970084_j_med-2026-1416_ref_034","doi-asserted-by":"crossref","unstructured":"Jin, Y, Jiang, J, Mao, W, Bai, M, Chen, Q, Zhu, J. Treatment strategies and molecular mechanism of radiotherapy combined with immunotherapy in colorectal cancer. Cancer Lett 2024;591:216858. https:\/\/doi.org\/10.1016\/j.canlet.2024.216858.","DOI":"10.1016\/j.canlet.2024.216858"},{"key":"2026042921165970084_j_med-2026-1416_ref_035","doi-asserted-by":"crossref","unstructured":"Krysko, DV, Garg, AD, Kaczmarek, A, Krysko, O, Agostinis, P, Vandenabeele, P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012;12:860\u201375. https:\/\/doi.org\/10.1038\/nrc3380.","DOI":"10.1038\/nrc3380"},{"key":"2026042921165970084_j_med-2026-1416_ref_036","doi-asserted-by":"crossref","unstructured":"Schumacher, TN, Schreiber, RD. Neoantigens in cancer immunotherapy. Science 2015;348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","DOI":"10.1126\/science.aaa4971"},{"key":"2026042921165970084_j_med-2026-1416_ref_037","doi-asserted-by":"crossref","unstructured":"Mole, R. Whole body irradiation\u00a0\u2013\u00a0radiobiology or medicine? Br J Radiol 1953;26:234\u201341. https:\/\/doi.org\/10.1259\/0007-1285-26-305-234.","DOI":"10.1259\/0007-1285-26-305-234"},{"key":"2026042921165970084_j_med-2026-1416_ref_038","doi-asserted-by":"crossref","unstructured":"Deng, L, Liang, H, Burnette, B, Beckett, M, Darga, T, Weichselbaum, RR, et al.. Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice. J\u00a0Clin Investig 2014;124:687\u201395. https:\/\/doi.org\/10.1172\/jci67313.","DOI":"10.1172\/JCI67313"},{"key":"2026042921165970084_j_med-2026-1416_ref_039","doi-asserted-by":"crossref","unstructured":"Du, S-S, Chen, G-W, Yang, P, Chen, Y-X, Hu, Y, Zhao, Q-Q, et al.. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys 2022;112:1243\u201355. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.162.","DOI":"10.1016\/j.ijrobp.2021.12.162"},{"key":"2026042921165970084_j_med-2026-1416_ref_040","doi-asserted-by":"crossref","unstructured":"Bagchi, S, Yuan, R, Engleman, EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 2021;16:223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","DOI":"10.1146\/annurev-pathol-042020-042741"},{"key":"2026042921165970084_j_med-2026-1416_ref_041","doi-asserted-by":"crossref","unstructured":"Lieu, CH, Renfro, LA, De Gramont, A, Meyers, JP, Maughan, TS, Seymour, MT, et al.. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD clinical trials program. J\u00a0Clin Oncol 2014;32:2975\u201382. https:\/\/doi.org\/10.1200\/jco.2013.54.9329.","DOI":"10.1200\/JCO.2013.54.9329"},{"key":"2026042921165970084_j_med-2026-1416_ref_042","doi-asserted-by":"crossref","unstructured":"Bradley, CJ, Yabroff, KR, Warren, JL, Zeruto, C, Chawla, N, Lamont, EB. Trends in the treatment of metastatic colon and rectal cancer in elderly patients. Med Care 2016;54:490\u20137. https:\/\/doi.org\/10.1097\/mlr.0000000000000510.","DOI":"10.1097\/MLR.0000000000000510"},{"key":"2026042921165970084_j_med-2026-1416_ref_043","doi-asserted-by":"crossref","unstructured":"Miller, RA. The aging immune system: primer and prospectus. Science 1996;273:70\u20134. https:\/\/doi.org\/10.1126\/science.273.5271.70.","DOI":"10.1126\/science.273.5271.70"},{"key":"2026042921165970084_j_med-2026-1416_ref_044","doi-asserted-by":"crossref","unstructured":"Murphy, CC, Sandler, RS, Sanoff, HK, Yang, YC, Lund, JL, Baron, JA. Decrease in incidence of colorectal cancer among individuals 50\u00a0years or older after recommendations for population-based screening. Clin Gastroenterol Hepatol 2017;15:903\u20139.e6. https:\/\/doi.org\/10.1016\/j.cgh.2016.08.037.","DOI":"10.1016\/j.cgh.2016.08.037"},{"key":"2026042921165970084_j_med-2026-1416_ref_045","doi-asserted-by":"crossref","unstructured":"Lv, M-Y, Chen, X-J, Chen, J-G, Zhang, B, Lin, Y-Y, Huang, T-Z, et al.. Nomogram for predicting overall survival time of patients with stage IV colorectal cancer. Gastroenterol Rep 2022;10:goac072. https:\/\/doi.org\/10.1093\/gastro\/goac072.","DOI":"10.1093\/gastro\/goac072"},{"key":"2026042921165970084_j_med-2026-1416_ref_046","doi-asserted-by":"crossref","unstructured":"Ueda, K, Yamada, T, Ohta, R, Matsuda, A, Sonoda, H, Kuriyama, S, et al.. BRAF V600E mutations in right-side colon cancer: heterogeneity detected by liquid biopsy. Eur J Surg Oncol 2022;48:1375\u201383. https:\/\/doi.org\/10.1016\/j.ejso.2022.01.016.","DOI":"10.1016\/j.ejso.2022.01.016"},{"key":"2026042921165970084_j_med-2026-1416_ref_047","doi-asserted-by":"crossref","unstructured":"Papagiorgis, PC, Zizi, AE, Tseleni, S, Oikonomakis, IN, Nikiteas, NI. The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location. Oncol Lett 2012;3:1129\u201335. https:\/\/doi.org\/10.3892\/ol.2012.621.","DOI":"10.3892\/ol.2012.621"},{"key":"2026042921165970084_j_med-2026-1416_ref_048","doi-asserted-by":"crossref","unstructured":"Koliaraki, V, Pallangyo, CK, Greten, FR, Kollias, G. Mesenchymal cells in colon cancer. Gastroenterology 2017;152:964\u201379. https:\/\/doi.org\/10.1053\/j.gastro.2016.11.049.","DOI":"10.1053\/j.gastro.2016.11.049"},{"key":"2026042921165970084_j_med-2026-1416_ref_049","doi-asserted-by":"crossref","unstructured":"Xi, Y, Yuefen, P, Wei, W, Quan, Q, Jing, Z, Jiamin, X, et al.. Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer. J\u00a0Transl Med 2019;17:1\u201322. https:\/\/doi.org\/10.1186\/s12967-019-2102-1.","DOI":"10.1186\/s12967-019-2102-1"},{"key":"2026042921165970084_j_med-2026-1416_ref_050","doi-asserted-by":"crossref","unstructured":"Zhong, M, Xiong, Y, Ye, Z, Zhao, J, Zhong, L, Liu, Y, et al.. Microbial community profiling distinguishes left-sided and right-sided colon cancer. Front Cell Infect Microbiol 2020;10:498502. https:\/\/doi.org\/10.3389\/fcimb.2020.498502.","DOI":"10.3389\/fcimb.2020.498502"},{"key":"2026042921165970084_j_med-2026-1416_ref_051","doi-asserted-by":"crossref","unstructured":"Siebenh\u00fcner, AR, G\u00fcller, U, Warschkow, R. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. BMC Cancer 2020;20:1\u20139. https:\/\/doi.org\/10.1186\/s12885-020-6710-1.","DOI":"10.1186\/s12885-020-6710-1"},{"key":"2026042921165970084_j_med-2026-1416_ref_052","doi-asserted-by":"crossref","unstructured":"Venderbosch, S, de Wilt, JH, Teerenstra, S, Loosveld, OJ, van Bochove, A, Sinnige, HA, et al.. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 2011;18:3252\u201360. https:\/\/doi.org\/10.1245\/s10434-011-1951-5.","DOI":"10.1245\/s10434-011-1951-5"},{"key":"2026042921165970084_j_med-2026-1416_ref_053","doi-asserted-by":"crossref","unstructured":"Van Rooijen, K, Shi, Q, Goey, K, Meyers, J, Heinemann, V, Diaz-Rubio, E, et al.. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer 2018;91:99\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.014.","DOI":"10.1016\/j.ejca.2017.12.014"},{"key":"2026042921165970084_j_med-2026-1416_ref_054","doi-asserted-by":"crossref","unstructured":"Stelzner, S, Radulova\u2010Mauersberger, O, Zschuppe, E, Kittner, T, Abolmaali, N, Puffer, E, et al.. Prognosis in patients with synchronous colorectal cancer metastases after complete resection of the primary tumor and the metastases. J\u00a0Surg Oncol 2019;120:438\u201345. https:\/\/doi.org\/10.1002\/jso.25578.","DOI":"10.1002\/jso.25578"},{"key":"2026042921165970084_j_med-2026-1416_ref_055","unstructured":"Cooper, H, Slemmer, J, editors. Surgical pathology of carcinoma of the colon and rectum. New York: Seminars in Oncology; 1991."},{"key":"2026042921165970084_j_med-2026-1416_ref_056","doi-asserted-by":"crossref","unstructured":"Blumberg, D, Paty, PB, Picon, AI, Guillem, JG, Klimstra, DS, Minsky, BD, et al.. Stage I rectal cancer: identification of high-risk patients. J\u00a0Am Coll Surg 1998;186:574\u201380. https:\/\/doi.org\/10.1016\/s1072-7515(98)00018-0.","DOI":"10.1016\/S1072-7515(98)00018-0"},{"key":"2026042921165970084_j_med-2026-1416_ref_057","doi-asserted-by":"crossref","unstructured":"Ueno, H, Konishi, T, Ishikawa, Y, Shimazaki, H, Ueno, M, Aosasa, S, et al.. Prognostic value of poorly differentiated clusters in the primary tumor in patients undergoing hepatectomy for colorectal liver metastasis. Surgery 2015;157:899\u2013908. https:\/\/doi.org\/10.1016\/j.surg.2014.12.025.","DOI":"10.1016\/j.surg.2014.12.025"},{"key":"2026042921165970084_j_med-2026-1416_ref_058","unstructured":"Wang, W, Yang, Z-L, Liu, J-Q, Yang, L-P, Yang, X-J, Fu, X. Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma. Tumori J 2014;100:667\u201374. https:\/\/doi.org\/10.1700\/1778.19276."}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1416\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:35:00Z","timestamp":1777498500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1416\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,27]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1416"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1416","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261416"}}